Winnipeg -13° C, Partly cloudy
Full Forecast
Finding your
information
©2021 FP Newspaper Inc.
Quick Links
Ways to support us
Replica E-Edition
Business
Arts & Life
Sports
Opinion
Media
Homes
Canstar Community News
Coupons
About Us
Finding your
information
Advertisement
Advertise With Us
By: The Canadian Press
Posted: 12:41 PM CST Friday, Dec. 3, 2021
Last Modified: 1:39 PM CST Friday, Dec. 3, 2021
OTTAWA – Canada is buying up to 1.5 million courses of oral antiviral treatments for COVID-19 in anticipation of them being approved by Health Canada.
Public Services and Procurement Minister Filomena Tassi rises during Question Period, in Ottawa, Friday, Dec. 3, 2021. Tassi says Canada has signed agreements to buy up 1.5 million courses of oral antiviral treatment for COVID-19. THE CANADIAN PRESS/Adrian Wyld
OTTAWA – Canada is buying up to 1.5 million courses of oral antiviral treatments for COVID-19 in anticipation of them being approved by Health Canada.
The government has signed up for an initial one million courses of antiviral treatment from Pfizer, once Health Canada endorses their safety and efficacy.The company submitted a request for approval to the federal drug regulator earlier this week.
Canada has also purchased 500,000 courses of Merck’s oral antiviral treatment for COVID-19, with the option to purchase another 500,000 once Health Canada approves the drug.
“Access to effective, easy-to-use treatments is critical to reducing the severity of COVID infections and will help save lives,” Procurement Minister Filomena Tassi said Friday.
A stock of antiviral medications will complement vaccines in fighting the pandemic, she said.
“It’s just another tool in the tool box, but an important one,” she said.
Some experts have hailed antiviral drugs as a game-changer in treating the disease, since they are designed to block the enzyme essential for viral replication.
“If successful, oral antiviral therapies … may help to reduce the severity or onset of illness in adults who contract, or have been exposed to, COVID-19. An oral treatment option may thus be an important tool to help address the ongoing global impact of the COVID-19 pandemic,” Pfizer Canada’s Kevin Mohamed said in a written statement Friday.
Merck’s clinical trial showed a 50 per cent reduced risk of hospitalization or death compared to placebo patients with mild or moderate COVID-19, for example.
A weekly look towards a post-pandemic future delivered to your inbox every Wednesday.
The oral medications will also be more accessible than the ones that need to be given intravenously, federal Health Minister Jean-Yves Duclos said Friday.
Current antivirals are only available to people in hospital, leaving them unavailable to people in remote regions or people with mild to moderate illness.
These new drugs could be prescribed and taken by patients at home.
“This treatment will drastically reduce the risk of hospitalization for both vaccinated and unvaccinated people,” Duclos said Friday.
Health Canada has prioritized its reviews of all COVID-19 vaccines and treatments, and has previously said it would work quickly and thoroughly on new drug applications that could help in fighting the pandemic.
This report by The Canadian Press was first published Dec. 3, 2021.
Advertisement
Advertise With Us
The Winnipeg Free Press invites you to share your opinion on this story in a letter to the editor. A selection of letters to the editor are published daily.
To submit a letter:
• fill out the form on this page, or
• email [email protected], or
• mail Letters to the Editor, 1355 Mountain Avenue, Winnipeg, Manitoba, R2X 3B6.
Letters must include the writer’s full name, address, and a daytime phone number. Letters are edited for length and clarity.
Advertisement
Advertise With Us
